Anaptys Announces Participation in September Investor Conferences

Rhea-AI Summary

AnaptysBio (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, has announced its participation in three major investor conferences in September 2025.

The company's leadership, including CEO Daniel Faga, will participate in fireside chats and one-on-one investor meetings at the Cantor Global Healthcare Conference (Sept. 3), Wells Fargo Healthcare Conference (Sept. 4), and Stifel Virtual Immunology and Inflammation Forum (Sept. 16). All sessions will be available via webcast on the company's investor relations website.

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:  

Cantor Global Healthcare Conference 2025, New York, NY

• Format – Fireside chat and one-on-one investor meetings
• Date and Time – Wednesday, Sept. 3, 2025 at 8:00am ET / 5:00am PT

2025 Wells Fargo Healthcare Conference, Boston, MA

• Format – Fireside chat and one-on-one investor meetings
• Date and Time – Thursday, Sept. 4, 2025 at 11:00am ET / 8:00am PT

Stifel 2025 Virtual Immunology and Inflammation Forum, Virtual

• Format – Fireside chat and one-on-one investor meetings
• Date and Time – Tuesday, Sept. 16, 2025 at 12:00pm ET / 9:00am PT

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. Replays of the webcasts will be available for at least 30 days following the events.

About Anaptys

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, being studied in celiac disease and ANB101, a BDCA2 modulator, both in Phase 1 trials. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com

FAQ

When is AnaptysBio (ANAB) presenting at the Cantor Global Healthcare Conference 2025?

AnaptysBio will present at the Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 8:00am ET in New York.

How can investors access AnaptysBio's conference presentations in September 2025?

Investors can access live webcasts of the fireside chats through AnaptysBio's investor relations website at https://ir.anaptysbio.com/presentations-and-events. Replays will be available for at least 30 days after the events.

Which investor conferences will AnaptysBio (ANAB) attend in September 2025?

AnaptysBio will attend three conferences: the Cantor Global Healthcare Conference in New York (Sept. 3), Wells Fargo Healthcare Conference in Boston (Sept. 4), and Stifel Virtual Immunology and Inflammation Forum (Sept. 16).

Who will represent AnaptysBio at the September 2025 investor conferences?

Daniel Faga, president and chief executive officer of AnaptysBio, and/or other members of the executive leadership team will represent the company at the conferences.